Skip to main content

Table 3 Multivariate statistic of gender, age, histology, smoking status, treat line, EGFR mutation and SFRP5 methylation for objective response rate (ORR) and disease control rate (DCR)

From: DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer

Variable

Objective response rate (ORR)

Disease control rate (DCR)

Univariate

Multivariate

Univariate

Multivariate

P value

P value

Hazard ratio (95% CI)

P value

P value

Hazard ratio (95% CI)

Gender (male / female)

0.188

0.881

0.926 (0.337-2.542)

0.001

0.115

2.117 (0.834-5.734)

Age (≤65 / >65)

0.351

0.078

2.295 (0.912-5.772)

0.291

0.791

1.110 (0.515-2.393)

Histology (adenocarcinoma / nonadenocarcinoma)

0.002

0.006

6.680 (1.712-26.057)

0.049

0.244

1.663 (0.707-3.915)

Line Treatment (first line / not-first line)

0.016

0.078

2.184 (0.917-5.200)

0.940

0.491

0.756 (0.341-1.678)

Smoking Status (smoker / nonsmoker)

0.016

0.262

0.526 (0.171-1.617)

0.001

0.188

0.524 (0.200-1.371)

EGFR Mutation (wide type / mutation)

<0.0001

<0.0001

7.695 (2.895-20.454)

<0.0001

0.002

3.255 (1.540-6.881)

SFRP5 Methylation (methylated / unmethylated)

0.222

0.650

0.734 (0.193-2.788)

0.04

0.106

0.434 (0.158-1.193)